Navigation Links
Hill-Rom Announces Agreement with Encompass Therapeutic Support Systems Adding New Surface Choice for Use with Hill-Rom Frames
Date:10/30/2008

successful in the marketplace, changes in customers' Medicare reimbursements, collections of accounts receivable, compliance with FDA regulations, antitrust litigation, potential exposure to product liability or other claims, failure of the Company's announced strategic initiatives and restructuring and realignment activities to achieve expected growth, future restructuring or realignment activities, efficiencies or cost reductions, disruptions in the Company's business or other adverse consequences resulting from the recent spin-off of the funeral service business, failure to realize the anticipated benefits of the spin-off, failure of the Company to execute its acquisition and business alliance strategy through the consummation and successful integration of acquisitions or entry into joint ventures or other business alliances, increased costs or unavailability of raw materials, labor disruptions, the ability to retain executive officers and other key personnel, and certain tax-related matters. For a more in depth discussion of these and other factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the period ended September 30, 2007, its Current Report on Form 8-K filed with the SEC on March 17, 2008, and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. The Company assumes no obligation to update or revise any forward- looking statements.


'/>"/>
SOURCE Hill-Rom
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year
2. Hill-Rom Holdings, Inc. Invites You to Join its Fiscal 2008 Third Quarter Earnings Webcast
3. Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities
4. Hill-Rom to Present at the Jefferies Healthcare Conference
5. Hill-Rom Innovative TotalCare(R) Bariatric Plus Therapy System Receives Gold Medical Device Excellence Award
6. Hill-Rom Announces Third Quarter 2008 Dividend
7. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
8. Hill-Rom to Present at the Citi Healthcare Conference
9. Hill-Rom to Present at the Bank of America 2008 Health Care Conference
10. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Second Quarter Earnings Webcast
11. Hill-Roms NaviCare(R) WatchChild(R) Solution Provides Enhanced Information Technology Solutions for Obstetrical Care
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data 48682 1Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data 48682 2Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data 48682 3AMA Cheers Senate Passage of Historic Tobacco Regulation Bill 48678 1AMA Cheers Senate Passage of Historic Tobacco Regulation Bill 48678 2Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 48674 1Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 48674 2Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 48674 3